In this poster you will learn:

• People who inject drugs (PWID) constitute 60% of the approximately 5 million people in the United States infected with hepatitis C virus (HCV). Successful HCV treatment leading to sustained viral response (SVR) is associated with increased survival, but to date successful treatment of PWIDs has been limited.
• Prior research has shown that treatment adherence and outcomes for other infectious diseases, such as tuberculosis (TB) and HIV, are improved among drug users when directly observed therapy (DOT) is administered at Methadone Maintenance Treatment (MMT) programs.
• To our knowledge, this is the first pilot study to evaluate the use of an artificial intelligence (AI) platform (AiCure, New York, NY) to measure and increase adherence to HCV therapy. The study was implemented in an opiate agonist treatment program that offers on-site HCV treatment by primary care providers.
• The (AI) platform uses software algorithms on smartphones to visually and automatically confirm participant identity, the medication, and medication ingestion (Figure 1). Participants receive automated reminders and precise dosing instructions. Study teams have access to real-time data for review and intervention.